ClinicalTrials.gg
CompletedNCT07392437DIAMINDUpdated Nov 19, 2026

Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and Identification of Its Associated Factors.

An interventional study of Questionnaire and Physical Exam in Diabetes Mellitus and Psychological Distress, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.

Enrollment
120th of 242
190 · median 187
Started
2026
with 10 others
No phase
100 of 352
22 open now
Registered
340th of 352
by date

Among the 352 studies in Diabetes Mellitus with a site in France, this one is the 120th largest by enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2026, is one of 100 with no phase, and was the 340th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 352 studies in Diabetes Mellitus with a site in France, or all of them as a file.
02

Study summary

Diabetes-related distress is a psychological construct associated with poorer glycaemic control in people living with diabetes. In France, few data are available on this topic and none focus specifically on adults with type 2 diabetes. Diabetes-related distress is not mentioned in the current French national guidelines on the management of type 2 diabetes, whereas international societies such as the ADA and, more recently, the EASD now recommend its regular assessment.

This single-centre observational study conducted in the endocrinology department of Nice University Hospital aims to estimate the prevalence of severe diabetes-related distress in adults with type 2 diabetes receiving usual care, and to identify associated clinical, psychosocial and lifestyle factors. Participants complete validated self-report questionnaires (PAID-20 for diabetes distress, WHOQOL-BREF for quality of life, and a modified Starting The Conversation dietary questionnaire), and clinical data are extracted from electronic medical records. The study does not modify usual medical management and participation consists only in completing the questionnaires and receiving feedback on the results.

03

Conditions studied

  • Diabetes Mellitus
  • Psychological Distress

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age ≥ 18 years).
  • Diagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications, and with no restriction regarding level. Patients with mixed diabetes (type 2 diabetes associated with pancreatic disease) may also be included if all of the following criteria are met: pancreatic disease detected on imaging, preserved C-peptide levels (> 200 pmol/L in the presence of normal blood glucose levels), and ≥ 25 kg/m².
  • Able to understand the study information and to complete the self-administered questionnaires.
  • Affiliated to the French social security system.
  • Has not objected to participation in the study (non-opposition procedure).

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Pregnant woman.
  • Any type of diabetes other than type 2 diabetes (e.g. type 1 diabetes, secondary or genetic diabetes).
  • Haemochromatosis.
  • Cystic fibrosis.
  • Current treatment with one of the following hyperglycaemic therapies: oral , drugs, dopaminergic agonists, interferon-alpha, or protease inhibitors.
  • History of partial or total pancreatectomy.
  • Ongoing genetic work-up for atypical diabetes.
  • Non-French-speaking patient.
  • Major neurocognitive disorder or physical/mental disability preventing completion of the questionnaires.
  • Adult under legal protection (guardianship or curatorship).
  • Refusal or subsequent withdrawal of non-opposition.
  • Any later paraclinical result finally revealing a type of diabetes other than type 2 diabetes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Other
    Patients

    Behavioral: Questionnaire and Physical Exam

Interventions

  • BehavioralQuestionnaire and Physical Exam

    Patients will be asked to complete questionnaires.

06

What researchers measure

Primary outcomes

  1. Prevalence of severe diabetes-related distress (PAID-20 score ≥ 40)

    Diabetes-related distress will be assessed using the Problem Areas In Diabetes scale (PAID-20). The PAID-20 includes 20 items scored from 0 to 4; the total raw score (0-80) is multiplied by 1.25 to obtain a total score ranging from 0 to 100, with higher scores indicating greater diabetes-related distress. Severe diabetes-related distress is defined as a PAID-20 total score ≥ 40. The primary endpoint is the proportion of participants with PAID-20 ≥ 40.

    Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)

Secondary outcomes

  1. Prevalence of severe diabetes-related distress by care setting (ambulatory vs hospitalized)

    Using the PAID-20 total score (0-100; higher scores indicate greater distress, severe distress defined as ≥ 40), the proportion of participants with severe diabetes-related distress will be calculated in two predefined subgroups: ambulatory patients (outpatient clinic and day hospital) and hospitalized patients (conventional hospitalization in endocrinology).

    Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)

  2. Factors associated with diabetes-related distress (PAID-20 score)

    The PAID-20 total score (0-100; higher scores indicate greater diabetes-related distress) will be analysed as a continuous variable. Decision-tree models (CHAID/CRT) will be used to explore associations between diabetes-related distress and predefined clinical, psychosocial and lifestyle variables.

    Time frame: Baseline (single assessment during usual care visit, within 3 days from inclusion)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Oct 2026, 6 months.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2027 → Oct 2026 and completion Jan 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Feb 6, 2026
StartActual
Apr 15, 2026
Primary completionActual
Oct 28, 2026was Jan 2027
CompletionActual
Oct 28, 2026was Jan 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Jan 15, 2027→Oct 28, 2026 (actual)
Nov 19, 2026
Study completion
Jan 15, 2027→Oct 28, 2026 (actual)
Nov 19, 2026
Enrollment
246→190 (actual)
Nov 19, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications, and with no restriction regarding HbA1c level. Managed for Patients with mixed diabetes (type 2 diabetes associated with pancreatic disease) may also be included if all of the following criteria are met: pancreatic disease detected on imaging, preserved C-peptide levels (> 200 pmol/L in the endocrinology departmentpresence of Nice University Hospital (conventional hospitalizationnormal blood glucose levels), day hospital, or outpatient consultation)and BMI ≥ 25 kg/m².
Oct 28, 2026
Show all 3 updates
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Jan 15, 2027→Oct 28, 2026 (now actual)
    Study completion Jan 15, 2027→Oct 28, 2026 (now actual)
    Enrollment 290 (estimated)→190 (actual)
    + 3 other changes: verification date, contact details and site details
  2. Oct 28, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications, and with no restriction regarding HbA1c level. Managed for Patients with mixed diabetes (type 2 diabetes associated with pancreatic disease) may also be included if all of the following criteria are met: pancreatic disease detected on imaging, preserved C-peptide levels (> 200 pmol/L in the endocrinology departmentpresence of Nice University Hospital (conventional hospitalizationnormal blood glucose levels), day hospital, or outpatient consultation)and BMI ≥ 25 kg/m².
  3. Oct 7, 2026
    Enrollment 246→290
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07392437
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Apr 15, 2026
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 19, 2026

Study contacts

Philippe CAROLI-BOSC, Dr
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion